Compare AbCellera Biologics Inc (ABCL) vs Byrna Technologies Inc (BYRN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Byrna Technologies Inc — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Byrna Technologies Inc trades at $5.97 (market cap $139.06M). The key difference: AbCellera Biologics Inc is far larger — about 16.9× Byrna Technologies Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Byrna Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | BYRN | |
|---|---|---|
Market Cap | $2.35B | $139.06M |
Sector | Health | Technology |
52-Week High | $8.12 | $32.30 |
52-Week Low | $2.78 | $4.96 |
Enterprise Value | $1.99B | $132.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
BYRN trades at $7.08, up 1.58% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $16.75. The company reported Q4 2025 EPS beat but a Q1 2026 miss, with revenue of $118.12M in 2025 and a net income margin of 7.3%. Recent news highlights strategic marketing expansions and upcoming Q2 2026 earnings.
Outlook is cautiously optimistic given strong analyst buy ratings (71.4%) and a high price target upside, though risks include negative cash flow, ongoing legal investigations, and margin pressure from retail channel shifts. Earnings growth and successful execution of new initiatives are critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →
